LEPU BIO-B (02157): Meiyouheng® (Vebecotuzumab Injection) Approved for R/M NPC Treatment

Stock News

Oct 30, 2025

LEPU BIO-B (02157) announced that the National Medical Products Administration (NMPA) has recently approved the market application of its self-developed candidate drug Meiyouheng® (Vebecotuzumab Injection) in China. The drug is an innovative epidermal growth factor receptor (EGFR)-targeting antibody-drug conjugate (ADC) for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). Meiyouheng® (Vebecotuzumab Injection) is the first approved EGFR-targeting ADC in China, marking a pioneering achievement in its class. The approval of Meiyouheng® represents another significant milestone for the company, as its launch for R/M NPC treatment is expected to improve patient outcomes. LEPU BIO-B also plans to expand the drug's indications based on this approval to accelerate the realization of its potential commercial value.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1145108614"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1145108614\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1145108614?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145108614","market":"us","top_or_hot":-1,"title":"LEPU BIO-B (02157): Meiyouheng® (Vebecotuzumab Injection) Approved for R/M NPC Treatment","media":"Stock News","content":"<p>LEPU BIO-B (02157) announced that the National Medical Products Administration (NMPA) has recently approved the market application of its self-developed candidate drug Meiyouheng® (Vebecotuzumab Injection) in China. The drug is an innovative epidermal growth factor receptor (EGFR)-targeting antibody-drug conjugate (ADC) for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). Meiyouheng® (Vebecotuzumab Injection) is the first approved EGFR-targeting ADC in China, marking a pioneering achievement in its class. The approval of Meiyouheng® represents another significant milestone for the company, as its launch for R/M NPC treatment is expected to improve patient outcomes. LEPU BIO-B also plans to expand the drug's indications based on this approval to accelerate the realization of its potential commercial value.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEPU BIO-B (02157): Meiyouheng® (Vebecotuzumab Injection) Approved for R/M NPC Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEPU BIO-B (02157): Meiyouheng® (Vebecotuzumab Injection) Approved for R/M NPC Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-30 18:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LEPU BIO-B (02157) announced that the National Medical Products Administration (NMPA) has recently approved the market application of its self-developed candidate drug Meiyouheng® (Vebecotuzumab Injection) in China. The drug is an innovative epidermal growth factor receptor (EGFR)-targeting antibody-drug conjugate (ADC) for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). Meiyouheng® (Vebecotuzumab Injection) is the first approved EGFR-targeting ADC in China, marking a pioneering achievement in its class. The approval of Meiyouheng® represents another significant milestone for the company, as its launch for R/M NPC treatment is expected to improve patient outcomes. LEPU BIO-B also plans to expand the drug's indications based on this approval to accelerate the realization of its potential commercial value.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1145108614","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145108614","pubTimestamp":1761819641,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LEPU BIO-B (02157) announced that the National Medical Products Administration (NMPA) has recently approved the market application of its self-developed candidate drug Meiyouheng® (Vebecotuzumab...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02157":"乐普生物-B"},"translate_title":"乐普生物-B(02157)：美优恒®（维贝妥珠单抗注射液）获批用于R/M鼻咽癌治疗","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02157":1},"content_text":"LEPU BIO-B (02157) announced that the National Medical Products Administration (NMPA) has recently approved the market application of its self-developed candidate drug Meiyouheng® (Vebecotuzumab Injection) in China. The drug is an innovative epidermal growth factor receptor (EGFR)-targeting antibody-drug conjugate (ADC) for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). Meiyouheng® (Vebecotuzumab Injection) is the first approved EGFR-targeting ADC in China, marking a pioneering achievement in its class. The approval of Meiyouheng® represents another significant milestone for the company, as its launch for R/M NPC treatment is expected to improve patient outcomes. LEPU BIO-B also plans to expand the drug's indications based on this approval to accelerate the realization of its potential commercial value.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}